Loading company financials…
Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0000318154
$437.23
+1.11% · delayed 15 min
$235.58B market value
What this company does
AMGEN develops and makes medicines. It took in $36.75B last year, which makes it a large company. Of every dollar it sells, about 21 cents is left as profit.
Financial health
Strong finances across the board.
From AMGEN INC's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
of 9 checks passed
Measured against FY2024, from the 10-K
Improved: +10.0%
$33.42B to $36.75B
Improved: +88.5%
$4.09B to $7.71B
Improved: +5.7 pts
61.5% to
It makes a profit rather than burning through money.
$7.71B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$9.96B cash from operations
It passes almost every standard check of financial strength.
Piotroski 8/9
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 13% a year for the next 10 years. Over the last 10 years it shrank by about 1% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 21 cents of every dollar of sales as profit, earning $7.71B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 66 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 51% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $7.71B and generated $9.96B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-08-05 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-04 | 2026-08-04 |
Financial figures are from AMGN's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.12
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.26
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +8.8 pts
12.2% to 21.0%
Deteriorated: -22.1%
$10.39B to $8.10B
Improved: -11.6%
$56.55B to $50.01B
Deteriorated: -23.8%
$11.97B to $9.13B
Changed: +69.5%
$1.10B to $1.86B
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 10% and 15%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.2% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 10.0% last year.
Manageable, but notable. Clearing its debt would take about 4.6 years of cash flow. For every $1 it owes, it owns $1.11 in assets.
Expensive. Investors pay $30.6 for every $1 of yearly profit, so a lot of future growth is already priced in.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-31 | 2026-07-29 |
| Major event announcement(8-K) | 2026-05-20 | 2026-05-19 |
| Major event announcement(8-K) | 2026-05-19 | 2026-05-19 |
| Quarterly report(10-Q) | 2026-05-01 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-30 | 2026-04-30 |
| Major event announcement(8-K) | 2026-04-22 | 2026-04-22 |
| Shareholder voting information(DEF 14A) | 2026-04-07 | 2026-05-19 |
| Major event announcement(8-K) | 2026-02-19 | 2026-02-17 |
| Annual report(10-K) | 2026-02-13 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-03 | 2026-02-03 |
| Major event announcement(8-K) | 2026-01-30 | 2026-01-30 |
| Quarterly report(10-Q) | 2025-11-05 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-04 | 2025-11-04 |
| Quarterly report(10-Q) | 2025-08-06 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-05 | 2025-08-05 |
| Major event announcement(8-K) | 2025-05-27 | 2025-05-23 |
| Quarterly report(10-Q) | 2025-05-02 | 2025-03-31 |
| Major event announcement(8-K) | 2025-05-01 | 2025-05-01 |
Coverage from the last 30 days
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar
Yahoo Finance ·
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Yahoo Finance ·
Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline
Yahoo Finance ·
Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?
Yahoo Finance ·
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Yahoo Finance ·
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Yahoo Finance ·
TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)
Yahoo Finance ·
Amgen Stock Signals Its Confidence. The Market Agrees.
Yahoo Finance ·
Rare-Disease Drug Tavneos Faces UK Withdrawal
Yahoo Finance ·
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
Yahoo Finance ·
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Yahoo Finance ·
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Yahoo Finance ·
Primary sources and further research